Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Cash from Operations (2016 - 2025)

Cytokinetics (CYTK) has disclosed Cash from Operations for 16 consecutive years, with 179689000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations changed N/A to 179689000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 512102000.0, a N/A change, with the full-year FY2025 number at 510009000.0, down 28.83% from a year prior.
  • Cash from Operations was 179689000.0 for Q4 2025 at Cytokinetics, down from 131600000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 26811000.0 in Q1 2022 to a low of 179689000.0 in Q4 2025.
  • A 5-year average of 88116470.59 and a median of 96205000.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: plummeted 369.85% in 2021, then rose 24.6% in 2023.
  • Cytokinetics' Cash from Operations stood at 44737000.0 in 2021, then tumbled by 119.48% to 98190000.0 in 2022, then rose by 24.6% to 74037000.0 in 2023, then tumbled by 37.09% to 101500000.0 in 2024, then crashed by 77.03% to 179689000.0 in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Cash from Operations are 179689000.0 (Q4 2025), 131600000.0 (Q1 2025), and 101500000.0 (Q3 2024).